Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113308 · ClinicalTrials.gov registry record · Phase 3
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
A Phase 3 study of Arthritis, Rheumatoid, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,208
- Enrollment target
- 20
- Study locations
NCT00113308 is a Phase 3 study of Arthritis, Rheumatoid that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,208 participants, above the 559-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (295% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00113308, a Phase 3 study of Arthritis, Rheumatoid, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,208 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.
Conditions Studied
Interventions
- DRUG GW406381
Study Locations (20)
California
- GSK Investigational Site - Anaheim
- GSK Investigational Site - Palm Desert
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Diego
- GSK Investigational Site - Santa Monica
- GSK Investigational Site - Upland
Alabama
- GSK Investigational Site - Anniston
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Huntsville
- GSK Investigational Site - Montgomery
- GSK Investigational Site - Montgomery
Arizona
- GSK Investigational Site - Glendale
- GSK Investigational Site - Scottsdale
- GSK Investigational Site - Tucson
- GSK Investigational Site - Tucson
Connecticut
- GSK Investigational Site - Bridgeport
- GSK Investigational Site - Danbury
Colorado
- GSK Investigational Site - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,208 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113308
The ClinicalTrials.gov registry entry for NCT00113308 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,208 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 559-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (295% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 1 intervention - of which GW406381 is the first listed.
NCT00113308 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00113308 about?
NCT00113308 is a clinical study titled "COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis". This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.
What is the current status of trial NCT00113308?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,208 participants. The study started on 2005-06. Estimated completion is 2006-09.
What conditions does trial NCT00113308 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT00113308?
The interventions under investigation include: GW406381 (DRUG).
Who is sponsoring clinical trial NCT00113308?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00113308 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
COMPLETED · Phase 3
-
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
COMPLETED · Phase 3
-
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
-
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.